To address this question, we validated eight plasma proteins (IL-17A, F5, FLT4, SFTPB, and GNPTG in lymphoma, TNFSF12, CCL3, and KIT in NSCLC) for response prediction and three plasma proteins (IL36G, SERPINC1, and LTA) for relapse monitoring. This evidence concerns the gene KIT and non-small cell lung carcinoma.